CTI Seeks ASP Payment For Zevalin; Medicare Cap Temporarily Lifted

After winning a short-term reprieve from Medicare's payment cap on radioimmunotherapies, Cell Therapeutics will focus on convincing CMS to pay for those drugs under Part B's average sales price formula